Akero Therapeutics (AKRO) Stock Price, News & Analysis

Company Overview

Akero Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for severe metabolic diseases, with an initial emphasis on nonalcoholic steatohepatitis (NASH). The company’s research platform leverages engineered versions of endocrine hormones to target key pathways involved in lipid metabolism, glucose regulation and tissue fibrosis. By harnessing the biology of fibroblast growth factor 21 (FGF21), Akero aims to address underlying drivers of metabolic dysfunction rather than merely treating symptoms.

The company’s lead product candidate, efruxifermin, is an Fc-FGF21 fusion protein designed to improve liver health and metabolic parameters in patients with NASH. Efruxifermin has demonstrated reductions in liver fat content, improvements in markers of liver injury and favorable changes in lipid and glucose profiles in early-phase clinical studies. Akero is advancing efruxifermin through pivotal trials, including global Phase 2 and Phase 3 studies, with the goal of achieving regulatory approval for patients with advanced liver fibrosis due to NASH.

Founded in 2017 and headquartered in Boston, Massachusetts, Akero Therapeutics operates research and development facilities in North America while engaging clinical sites across the United States and Europe. The company’s scientific leadership comprises experts in metabolic disease biology, protein engineering and drug development, supported by advisory collaborations with leading academic institutions. Akero’s board includes seasoned biotech investors and executives who guide its strategic direction.

In addition to its lead program, Akero is exploring preclinical candidates that modulate other hormone pathways implicated in cardiometabolic and fibrotic disorders. Through partnerships with contract research organizations and regulatory agencies, the company aims to expand its pipeline and ultimately deliver new treatment options for patients suffering from metabolic and liver diseases worldwide.

Key Stats

• Today's Range: $44.60 to $46.13
• 50-Day Range: $45.44 to $56.28
• 52-Week Range: $21.34 to $58.40
• Volume: 905,913 shs
• Average Volume: 934,066 shs
• Market Capitalization: $3.65 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $81.57
• Consensus Rating: Buy

Akero Therapeutics Stock Analysis - MarketRank™

Akero Therapeutics scored higher than 78% of companies evaluated by MarketBeat, and ranked 226th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Akero Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Akero Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Akero Therapeutics are expected to decrease in the coming year, from ($3.99) to ($4.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Akero Therapeutics is -22.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Akero Therapeutics is -22.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Akero Therapeutics has a P/B Ratio of 3.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.53% of the outstanding shares of Akero Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Akero Therapeutics has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in Akero Therapeutics has recently increased by 13.55%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Akero Therapeutics does not currently pay a dividend.

Dividend Growth

Akero Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.75

Percentage of Shares Shorted

11.53% of the outstanding shares of Akero Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Akero Therapeutics has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in Akero Therapeutics has recently increased by 13.55%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 1.48

News Sentiment

Akero Therapeutics has a news sentiment score of 1.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Akero Therapeutics this week, compared to 7 articles on an average week.

Search Interest

1 people have searched for AKRO on MarketBeat in the last 30 days.

MarketBeat Follows

5 people have added Akero Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Akero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,612,680.00 in company stock.

Percentage Held by Insiders

Only 7.07% of the stock of Akero Therapeutics is held by insiders.

AKRO Stock Analysis - Frequently Asked Questions

How have AKRO shares performed this year?

Akero Therapeutics' stock was trading at $27.82 at the beginning of the year. Since then, AKRO shares have increased by 64.0% and is now trading at $45.62.

How were Akero Therapeutics' earnings last quarter?

Akero Therapeutics, Inc. (NASDAQ:AKRO) released its quarterly earnings data on Friday, August, 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.97) by $0.11.

When did Akero Therapeutics IPO?

Akero Therapeutics (AKRO) raised $75 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI served as the underwriters for the IPO and Roth Capital Partners was co-manager.

Who are Akero Therapeutics' major shareholders?

Top institutional shareholders of Akero Therapeutics include General Atlantic L.P. (7.17%), State Street Corp (3.43%), Bellevue Group AG (2.48%) and Alkeon Capital Management LLC (2.31%). Insiders that own company stock include Skorpios Trust, G Walmsley Graham, Andrew Cheng, Jonathan Young, Timothy Rolph, Seth Loring Harrison, Catriona Yale, William Richard White, Patrick Lamy, Scott A Gangloff and Tomas J Heyman.
View institutional ownership trends.

How do I buy shares of Akero Therapeutics?

Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Akero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Akero Therapeutics investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 8/08/2025
• Today: 9/03/2025
• Next Earnings (Estimated): 11/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AKRO
• CIK: 1744659
• Web: www.akerotx.com
• Phone: (650) 487-6488
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Akero Therapeutics: $81.57
• High Price Target: $109.00
• Low Price Target: $64.00
• Potential Upside/Downside: +78.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$252.06 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -15.84%
• Return on Assets: -14.59%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 12.66
• Quick Ratio: 12.66

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.82 per share
• Price / Book: 3.56

Miscellaneous

• Outstanding Shares: 79,990,000
• Free Float: 74,334,000
• Market Cap: $3.65 billion
• Optionable: Optionable
• Beta: -0.24